These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 12845508)

  • 1. Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid.
    Fager G; Cullberg M; Eriksson-Lepkowska M; Frison L; Eriksson UG
    Eur J Clin Pharmacol; 2003 Aug; 59(4):283-9. PubMed ID: 12845508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
    Johansson LC; Frison L; Logren U; Fager G; Gustafsson D; Eriksson UG
    Clin Pharmacokinet; 2003; 42(4):381-92. PubMed ID: 12648028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran.
    Eriksson UG; Johansson S; Attman PO; Mulec H; Frison L; Fager G; Samuelsson O
    Clin Pharmacokinet; 2003; 42(8):743-53. PubMed ID: 12846595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.
    Eriksson UG; Bredberg U; Gislén K; Johansson LC; Frison L; Ahnoff M; Gustafsson D
    Eur J Clin Pharmacol; 2003 May; 59(1):35-43. PubMed ID: 12743672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran.
    Sarich TC; Teng R; Peters GR; Wollbratt M; Homolka R; Svensson M; Eriksson UG
    Clin Pharmacokinet; 2003; 42(5):485-92. PubMed ID: 12739986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
    Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
    Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis.
    Eriksson UG; Mandema JW; Karlsson MO; Frison L; Gisleskog PO; Wählby U; Hamrén B; Gustafsson D; Eriksson BI
    Clin Pharmacokinet; 2003; 42(7):687-701. PubMed ID: 12844328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
    Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers.
    Johansson LC; Andersson M; Fager G; Gustafsson D; Eriksson UG
    Clin Pharmacokinet; 2003; 42(5):475-84. PubMed ID: 12739985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran in young healthy Japanese men.
    Wernevik LC; Nyström P; Johnsson G; Nakanishi T; Eriksson UG
    Clin Pharmacokinet; 2006; 45(1):77-84. PubMed ID: 16430312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects.
    Wolzt M; Wollbratt M; Svensson M; Wåhlander K; Grind M; Eriksson UG
    Eur J Clin Pharmacol; 2003 Oct; 59(7):537-43. PubMed ID: 12955372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions.
    Bredberg E; Andersson TB; Frison L; Thuresson A; Johansson S; Eriksson-Lepkowska M; Larsson M; Eriksson UG
    Clin Pharmacokinet; 2003; 42(8):765-77. PubMed ID: 12846597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers.
    Dorani H; Schützer KM; Sarich TC; Wall U; Logren U; Ohlsson L; Eriksson UG
    Eur J Clin Pharmacol; 2007 Jun; 63(6):571-81. PubMed ID: 17387462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparable pharmacokinetics and pharmacodynamics of melagatran in Japanese and caucasian volunteers after oral administration of the direct thrombin inhibitor ximelagatran.
    Wernevik LC; Nyström P; Andersson M; Johnsson G; Bylock A; Nakanishi T; Eriksson UG
    Clin Pharmacokinet; 2006; 45(1):85-94. PubMed ID: 16430313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis.
    Wåhlander K; Lapidus L; Olsson CG; Thuresson A; Eriksson UG; Larson G; Eriksson H
    Thromb Res; 2002 Aug; 107(3-4):93-9. PubMed ID: 12431473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction.
    Christersson C; Oldgren J; Bylock A; Wallentin L; Siegbahn A
    J Thromb Haemost; 2005 Oct; 3(10):2245-53. PubMed ID: 16194202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model.
    Wåhlander K; Eriksson-Lepkowska M; Nyström P; Eriksson UG; Sarich TC; Badimon JJ; Kalies I; Elg M; Bylock A
    Thromb Haemost; 2006 Mar; 95(3):447-53. PubMed ID: 16525572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low potential for interactions between melagatran/ximelagatran and other drugs, food, or alcohol.
    Wolzt M; Sarich TS; Eriksson UG
    Semin Vasc Med; 2005 Aug; 5(3):254-8. PubMed ID: 16123912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers.
    Sarich TC; Schützer KM; Wollbratt M; Wall U; Kessler E; Eriksson UG
    J Clin Pharmacol; 2004 Aug; 44(8):935-41. PubMed ID: 15286098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men.
    Johansson S; Wåhlander K; Larson G; Ohlsson L; Larsson M; Eriksson UG
    Blood Coagul Fibrinolysis; 2003 Oct; 14(7):677-84. PubMed ID: 14517494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.